Genetic analysis reveals disease-causing protein drug targets
An analysis of blood protein levels has supported drug target prioritisation by identifying the causal effects of proteins on diseases, a team has shown.
List view / Grid view
An analysis of blood protein levels has supported drug target prioritisation by identifying the causal effects of proteins on diseases, a team has shown.
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…
A new study shows astrocytes derived from monogenic Parkinson’s patients have metabolic alterations that mean they could be contributing to disease progression.
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
An engineered form of the SMOC1 protein has shown success as a type 2 diabetes treatment in animal models, say researchers.
Scientists have patented their technique of inhibiting cellular growth factor signalling to stop SARS-CoV-2 replication and treat COVID-19.
Researchers demonstrate that their novel small molecule, which activates the STING protein, supresses tumour growth and metastasis in a murine model of aggressive melanoma.
Researchers observed new structures of alpha-synuclein aggregates in their study exploring how the presence of cell membrane phospholipids impacts protein aggregation.
A study has shown that inhibiting sortilin, a neuroprotein known to have increased expression in cancers, reduces pancreatic cancer invasiveness in vitro.
Using cryogenic electron microscopy, scientists have observed the interaction between antibodies and their target molecules, providing information that could be utilised in the development of synthetic antibodies.
Researchers have found that the SARS-CoV-2 nucleocapsid protein may help the virus to spread from cell to cell, providing a drug target.
A protein called PPP1R1B has been revealed as a drug target for pancreatic cancer as it stopped the metastasis of tumours in mice.
A team has developed a predictive tool called TransComp-R which could be used to reveal whether new drugs that have been effective in animals will have positive outcomes in humans.
Researchers have shown that using antisense oligonucleotides to reduce the levels of prion protein in lab animals with prion disease can extended their survival.
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.